



COPY OF PAPERS
ORIGINALLY FILED

1614

Please print plus sign inside this box → ☐

PTO/SB/21 (08-00)
Approved for use through 10/31/02. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Applicati n Numb r	09/836,073
Filing Date	April 16, 2001
First Named Inventor	Asim DASGUPTA
Group Art Unit	1814
Examiner Name	To Be Assigned
Attorney Docket No.	220002054822

Total Number Of Pages In This Submission

6

RECEIVED
FEB 05 2002
TECH CENTER 1600/2900

ENCLOSURES (check all that apply)

- | | | |
|---|---|---|
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Assignment Papers
(for an Application) | <input type="checkbox"/> After Allowance Communication to Group |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interference |
| <input type="checkbox"/> Amendment / Reply | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Group
(Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declarations | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address | <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return postcard |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Terminal Disclaimer | |
| <input checked="" type="checkbox"/> Information Disclosure Statement; PTO form 1449 | <input type="checkbox"/> Request for Refund | |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> CD, Number of CD(s) _____ | |

RECEIVED
APR 03 2002
TECH CENTER 1600/2900

Remarks

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT


Firm or Individual Name	Kate H. Murashige Registration No. 29,959
Signature	<i>Kate H. Murashige</i>
Date	January 11, 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on January 11, 2002.

Garee A. Hahey
Garee A. Hahey

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



1614 #7
MW

PATENT
Docket No. 220002054889

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed Assistant Commissioner for Patents, Washington, D.C. 20231, on January 11, 2002.

Garee A. Haney
Garee A. Haney

RECEIVED
APR 03 2002
TECH CENTER 1600/2900
FEB 05 2001
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Asim DASGUPTA et al.

Serial No.: 09/836,073

Filing Date: April 16, 2001

For: METHODS TO INHIBIT VIRAL
REPLICATION

Examiner: To Be Assigned

Group Art Unit: 1614

**INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97**

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 09/316,630, filed May 21, 1999, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of * is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of * is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to

charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **220002054822**. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: January 11, 2002

Respectfully submitted,

By: Kate H. Murashige
Kate H. Murashige
Registration No. 29,959

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5112
Facsimile: (858) 720-5125

Form PTO-1449

Docket Number 220002054822

Application Number 09/836,073

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)


Applicant

Asim DASGUPTA et al.

Filing Date April 16, 2001

Group Art Unit 161

Mailing Date January 11, 2002



RECEIVED
FEB 05 2002
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	1.	04/1996	WO 96/11211	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	2.	Agol, Adv. Virus Res. (1991) 40:103-180
	3.	Agrawal, TIBTACH Vol. 14:376-387
	4.	Bandopadhyay et al., J. Virol. (1992) 66:6249-6256
	5.	Belsham et al., J. Virol. (1990) 64:5389-5395
	6.	Borman et al., Gen. Virol. (1993) 74:1775-1788
	7.	Borman et al., Virology (1992) 188:685-696
	8.	Borovjagin et al., Nucleic Acids Res. (1991) 19:4999-5005
	9.	Brown et al., Virology (1979) 97:376-405
	10.	Chambers et al., Journal of Biological Chemistry (1988) 263(34):18043-18061
	11.	Chang et al., J. Virol. (1993) 67:6716-6725
	12.	Chang et al., J. Virol. (1994) 68(11):7008-7020
	13.	Coward et al., J. Cell. Biochem. (1991) Suppl. 15E, abstract M311, p.82
	14.	Coward et al., J. Virol. (1992) 66:286-295
	15.	Das et al., J. Virol. (1994) 68(11):7200-7211
	16.	del Angel et al., Proc. Natl. Acad. Sci. USA (1989) 86:8299-8303
	17.	Dorner et al., J. Virol. (1984) 50:507-514

RECEIVED
APR 03 2002
TECH CENTER 1600/2900

EXAMINER: (examiner)

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 220002054822

Application Number 09/836,073

Applicant

Asim DASGUPTA et al.

Filing Date April 16, 2001

Group Art Unit 1614

Mailing Date January 11, 2002

- | | |
|-----|---|
| 18. | Gebhard et al., J. Virol. (1992) 66:3101-3109 |
| 19. | Glass et al., Virology (1993) 193:842-852 |
| 20. | Hellen et al., Proc. Natl. Acad. Sci. USA (1993) 90:7642-7646 |
| 21. | International Search Report based on International Application No. PCT/US99/11281 |
| 22. | Jackson et al., Trends Biochem. Sci. (1990) 15:477-483 |
| 23. | Jang et al., Genes Dev. (1990) 4:1560-1572 |
| 24. | Kitamura et al., Nature (1981) 291:547-553 |
| 25. | Kohara et al., J. Virol. (1992) 66:1476-1483 |
| 26. | Kozak, Microbiol. Rev. (1983) 47:1-45 |
| 27. | Luz et al., FEBS Letters (1990) 269:311-314 |
| 28. | Luz et al., Virology (1991) 65:6486-6494 |
| 29. | Macejak et al., Nature (1991) 353:90-94 |
| 30. | Meerovitch et al., Genes Dev. (1989) 3:1026-1034 |
| 31. | Meerovitch et al., J. Virol. (1993) 67:3798-3807 |
| 32. | Najita, Proc. Natl. Acad. Sci. USA (1990) 87:5846-5850 |
| 33. | Oh et al., Genes Dev. (1992) 6:1643-1653 |
| 34. | Pelletier et al., J. Virol. (1988) 62:4486-4492 |
| 35. | Pelletier et al., Nature (1988) 334:320-325 |
| 36. | Pestova et al., J. Virol. (1991) 65:6194-6204 |
| 37. | Pilipenko et al., Cell (1992) 68:119-131 |
| 38. | Racaniello et al., Proc. Natl. Acad. Sci. USA (1981) 78:4887-4891 |
| 39. | Skinner et al., J. Mol. Biol. (1989) 207:379-392 |
| 40. | Stull et al., Pharmaceutical Research 12(4):465-483 |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.